Incendia Therapeutics
Susan Macdonald is an experienced professional in the life science industry, currently serving as the Vice President of R&D Strategy and Program Management at Incendia Therapeutics. With a background in project management and strategic development, Susan has held various leadership roles in companies such as Hubble Therapeutics, Aldeyra Therapeutics, and Alexion Pharmaceuticals. Their expertise also extends to consulting as the Principal and Founder of Sixteen Hands Biopharma Consulting. Susan's academic background includes a Ph.D. in Cellular and Molecular Physiology from UMass Chan Medical School and a B.S. in Biology from Hobart and William Smith Colleges.
Incendia Therapeutics
Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.